Last reviewed · How we verify
rMenB+OMV NZ vaccine
rMenB+OMV NZ vaccine is a Meningococcal serogroup B vaccine Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B. Also known as: Bexsero.
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain.
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
At a glance
| Generic name | rMenB+OMV NZ vaccine |
|---|---|
| Also known as | Bexsero |
| Sponsor | GlaxoSmithKline |
| Drug class | Meningococcal serogroup B vaccine |
| Target | Neisseria meningitidis serogroup B surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
rMenB+OMV NZ contains recombinant meningococcal proteins (rMenB) combined with outer membrane vesicles (OMV) derived from a New Zealand epidemic strain of N. meningitidis serogroup B. The vaccine elicits both humoral and cellular immune responses, generating bactericidal antibodies that target surface antigens of serogroup B meningococci, thereby providing protection against invasive meningococcal disease.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection (PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (PHASE3)
- A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age (PHASE4)
- BIYELA - Bexsero Immunisation in Young Women in Africa (PHASE3)
- Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age (PHASE3)
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults (PHASE3)
- A Sourcing Study to Collect Human Blood Samples From Healthy Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rMenB+OMV NZ vaccine CI brief — competitive landscape report
- rMenB+OMV NZ vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about rMenB+OMV NZ vaccine
What is rMenB+OMV NZ vaccine?
How does rMenB+OMV NZ vaccine work?
What is rMenB+OMV NZ vaccine used for?
Who makes rMenB+OMV NZ vaccine?
Is rMenB+OMV NZ vaccine also known as anything else?
What drug class is rMenB+OMV NZ vaccine in?
What development phase is rMenB+OMV NZ vaccine in?
What are the side effects of rMenB+OMV NZ vaccine?
What does rMenB+OMV NZ vaccine target?
Related
- Drug class: All Meningococcal serogroup B vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroup B surface antigens
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B
- Also known as: Bexsero
- Compare: rMenB+OMV NZ vaccine vs similar drugs
- Pricing: rMenB+OMV NZ vaccine cost, discount & access